• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: Opioid pain sales to hit $18.4B in the U.S. by 2020

Report: Opioid pain sales to hit $18.4B in the U.S. by 2020

July 17, 2017
CenterWatch Staff

Informa Pharma Intelligence, a healthcare and pharmaceutical data and analysis firm, released its “Snapshot of the Opioid Market.” The report and infographic chart the opioid industry’s journey into an $18.4B annual market in the U.S. by 2020 and its attempts to combat the ongoing national crisis around opioid abuse.

Opioids: Past, Present, Future

Opioid prescriptions constitute more than half of the total prescription pain market, with Pfizer leading the industry in terms of R&D involvement in pain therapies. However, research shows the industry has been relatively slow to respond to the growing national crisis haunting the industry since OxyContin hit the market in 1995. According to the most recent CDC Data, opioid deaths have been steadily on the rise in the U.S. since 1999.

“At the same time the opioid market is expanding, deaths from opioid abuse are growing. The CDC estimates that more than 33,000 people died from opioid related causes in the U.S. in 2015 alone. It’s been a fascinating development to see how the FDA and the pharmaceutical industry have reacted to a crisis it unfortunately had a hand in creating.” said Michael Hay, head of Intelligence Products for Informa Pharma.

Late stage clinical trial data reveals that R&D effort in opioids is being directed toward formulations with abuse-deterrent properties. There a currently 15 opioids with abuse-deterrent formulas in late stage development from pharmaceutical companies, including Teva Pharmaceuticals and Elite Pharmaceuticals.

“Pushing for more ADF drugs has been a critical step towards curbing opioid abuse, while making sure the millions of people in need of pain medication have adequate access to the relief they need. However, how much this impacts the growing crisis remains to be seen as pharmaceutical companies pour more money into clinical trials and new finely tuned formulas over the next few years,” Hay commented.

Professional Perspectives

Informa Pharma Intelligence’s Biomedtracker and SERMO surveyed 30 U.S. primary care physicians treating patients with chronic pains that prescribe opioids to better understand first-hand how these controversial drugs are perceived. Findings suggest:

  • Half of the physicians surveyed think abuse-deterrent opioids will play no or only a slightly impactful role in combatting the opioids epidemic in the U.S.
  • Half of the physicians prescribe opioids to just 0-20% of their patients to treat chronic pain.
  • The majority of physicians surveyed don’t know if legislation has been adopted in their state requiring that abuse-deterrent opioids be covered by insurers.

Upcoming Events

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • MachineLearning-360x240.png

    Industry Using AI/ML to Improve Data, Quality and Trial Management, Survey Says

  • VirtualTraining-360x240.png

    Virtual Training Evolves into More In-Depth Learning, Improved Communications

  • SurveywBlueBackground-360x240.png

    Mid-Study Updates Delay Trials At Least a Month, CSDD Report Finds

  • Real-TimeData-360x240.png

    Real-Time Data Helped Sponsors Respond to Sites’ Needs During the Pandemic

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing